NCT05253131 2026-02-11Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for SarcomasUniversity of Alabama at BirminghamPhase 2 Not yet recruiting41 enrolled
NCT03433183 2023-12-26SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath TumorsSarcoma Alliance for Research through CollaborationPhase 2 Completed21 enrolled